Home/Filings/4/0001209191-07-007511
4//SEC Filing

Molecular Insight Pharmaceuticals, Inc. 4

Accession 0001209191-07-007511

CIK 0001340752operating

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 4:09 PM ET

Size

12.0 KB

Accession

0001209191-07-007511

Insider Transaction Report

Form 4
Period: 2007-02-01
Babich John W
DirectorPresident, CEO and CSO
Transactions
  • Conversion

    Common Stock

    2007-02-01+27,70227,702 total
  • Conversion

    Series A Convertible Preferred Stock

    2007-02-016410 total
    Common Stock (27,702 underlying)
Footnotes (4)
  • [F1]The reporting person held 641 shares of Series A Convertible Preferred Stock. In connection with the issuer's IPO, the Series A Convertible Preferred Stock automatically converted into 27,702 shares of Common Stock, which number of shares includes accrued and unpaid dividends on the Series A Preferred Stock as of February 1, 2007.
  • [F2]Immediately.
  • [F3]Not applicable.
  • [F4]The reporting person holds Employee Stock Options to purchase 594,167 shares of the Common Stock, as previously reported on Form 3.

Issuer

Molecular Insight Pharmaceuticals, Inc.

CIK 0001340752

Entity typeoperating
IncorporatedMA

Related Parties

1
  • filerCIK 0001340752

Filing Metadata

Form type
4
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:09 PM ET
Size
12.0 KB